United States: As per the expert’s report, the second consecutive year of respiratory syncytial virus (RSV) vaccines being offered to older adults, this fall season.
There are several questions that revolve around the RSV vaccines that patients have over the past several weeks. Moreover, this year, there is the latest fear of Guillain-Barré syndrome.
Who should be vaccinated?
According to the CDC, people above the age of seventy-five should receive an RSV shot if they haven’t already,
Those whose ages lie between60 and 74 and have health conditions such as heart or lung diseases, as well as weakened immune systems, have been recommended to take the vaccine, too, dailykos.com reported.
However, the CDC has not recommended it for at-risk people aged 50 to 59. This is because the ACIP panel said they had little data on which to base their recommendation.
Availability of vaccines
According to the experts, there are three options available, such as Arexvy and Abrysvo, which have been in the market for two years now; now there is a newcomer – mResvia from Moderna.
There are three options: Arexvy and Abrysvo are in their second year of availability, and there is a newcomer from Moderna called mResvia.
As per the reports, mResvia, which has an mRNA platform, was given approval in May 2024 – although a bit too late when it would finally hit the shelves in many pharmacies for this fall.
However, we have little evidence of its performance in the real world or the experience of the newest one.
Experts, however, give more preference to the Arexvy brand from GSK over the Abrysvo brand from Pfizer, dailykos.com reported.
Protection against Guillain-Barré syndrome (GBS)
Currently, there are no head-to-head studies or post-approval surveillance that found a possibility or slight risk of Guillain-Barré syndrome (GBS) with Abrysvo more than Arexvy.
Moreover, there are no reports of Guillain-Barré syndrome among people in the clinical trials, which prompted them to approve mResvia.